Filing Flows › Dentsply Sirona (XRAY) › Stock forecast & fair value
Dentsply Sirona (XRAY) stock forecast and fair value
Dentsply Sirona (XRAY) trades at $9.46. 15 analysts' median price target is $11.00 (+16%), from $9.00 to $17.00. Across 16 valuation methods the middle fair value is $16.33 (+73%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/EBITDA vs peers | $11.20 | $16.33 | $22.69 | +73% |
| EV/EBITDA vs peers, weighted | $11.01 | $12.45 | $18.52 | +32% |
| EV/Sales vs peers | $30.37 | $48.41 | $82.43 | +412% |
| EV/Sales vs peers, weighted | $43.82 | $61.75 | $111.08 | +553% |
| EV/Sales vs peers, matched | $15.90 | $22.29 | $41.16 | +136% |
| EV/Sales vs peers, growth & margin adjusted | $17.85 | $29.49 | $45.91 | +212% |
| Residual income | $2.84 | $2.95 | $3.07 | -69% |
| Analysts' price targets | $9.00 | $11.40 | $17.00 | +21% |
| Owner earnings capitalized | $3.52 | $4.11 | $4.93 | -57% |
| Shareholder yield (dividends + buybacks) | $9.40 | $10.96 | $13.15 | +16% |
Dentsply Sirona's latest quarter
Dentsply Sirona, Q3 2026: revenue $836M (-8% year over year), operating margin 4.4%, net loss $3.0M, operating cash flow $32.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for XRAY stock?
The median of 15 analysts' 12-month targets is $11.00, +16% from $9.46; the range is $9.00 to $17.00. The average rating is hold.
What is Dentsply Sirona's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $0.00 and $61.75, with a middle value of $16.33 against a price of $9.46. Each method's assumptions are on the page.
Does Dentsply Sirona usually beat earnings estimates?
It beat the consensus EPS estimate in 20% of the quarters on record.
Is XRAY stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.